NHS wasting hundreds of millions of pounds says Marsh

Speaking at a conference examining healthcare acquired infections (HAIs), Robert Wendin, Head of Marsh’s Healthcare Practice for Europe, the Middle East and Africa, said that hospitals which invest in MRSA prevention can demonstrate tangible financial returns.

Mr Wendin said: “The moral duty to patients already provides a clear reason to tackle MRSA. Our analysis shows that there is now a strong financial one as well. “We calculate that HAIs can cost an average 300-bed hospital over £1.5